Pfizer has lagged behind the broader market over the past year, but analysts maintain a cautiously optimistic outlook on the ...

60 Guilders and Sentry Capital stepped up. 60 Guilders, run by CEO Kevin Chisholm, purchased the mezzanine loan for $80 ...

In an upward revision of its full-year guidance, Pfizer said it now expects adjusted earnings per share for 2025 to range between 2.90 dollars and 3.10 dollars, compared to its previous forecast of ...

About Vepdegestrant Vepdegestrant is an investigational, orally bioavailable PROteolysis TArgeting Chimera (PROTAC) estrogen receptor degrader. Vepdegestrant is being developed as a potential ...

A $150 million redevelopment plan will convert the former Pfizer campus in Peapack-Gladstone into a senior living community.

CureVac N.V., a multinational biotech company developing a new class of transformative medicines based on messenger RNA (mRNA ...

Bushburg got a $320 million construction loan for its office-to-residential conversion of 80 Pine Street, one of the city’s ...

New York City’s housing shortage may find an unlikely hero in its glut of underused office buildings, according to Brad Lander.

A massive New York housing project is one step closer to breaking the ground. The New York City Council Land Use and Zoning ...

TF Cornerstone will convert Tower 57, a 397,354-square-foot office tower in Manhattan, into a 350-unit multifamily property.

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

While a substantial portion of pipeline assets are externally sourced, many Big Pharmas are tapping into incubators and ...